 |
 |
L-DOPA ethyl ester to treat Parkinson's disease (Assignee -- Yissum Research Development Company of the Hebrew University of Jerusalem Teva Pharmaceutical Industries Ltd.) Source: MicroPatent MicroPatent via Individual Inc. : Abstract: Patients suffering from Parkinson's disease are treated by administering a composition which contains an active ingredient and a pharmaceutically acceptable carrier. The active ingredient comprises L-DOPA ethyl ester in an amount which is at least 97% by weight of the active ingredient and L-DOPA in an amount which is less than 1% by weight of the active ingredient. Ex Claim Text: A method of treating a patient suffering from Parkinson's disease which comprises administering to the patient a therapeutically effective amount of a composition which comprises: L-DOPA ethyl ester derived from pharmaceutically acceptable, crystalline, non-hygroscopic L-DOPA ethyl ester of at least ninety-seven percent purity and containing less than one percent by weight L-DOPA, characterized in that the amount of L-DOPA ethyl ester decreases by less than four percent after one month at forty degrees Celsius; and a pharmaceutically acceptable carrier. a pharmaceutically acceptable carrier. Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Teva Pharmaceutical Industries Ltd. Patent Number: 5607969 Issue Date: 1997 03 04 Inventor(s): Milman, IsaacVeinberg, Alexander Atlas, Daphne Melamed, Eldad If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787. [03-11-97 at 14:21 EST, Copyright 1997, MicroPatent]